161,687 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Callan Family Office LLC

Callan Family Office LLC bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 161,687 shares of the company’s stock, valued at approximately $3,979,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC raised its holdings in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Elanco Animal Health in the 2nd quarter worth approximately $38,000. Root Financial Partners LLC boosted its stake in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $41,000. Finally, Torren Management LLC bought a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $46,000. 97.48% of the stock is currently owned by institutional investors.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O’neill acquired 3,998 shares of the stock in a transaction dated Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the transaction, the insider directly owned 87,832 shares of the company’s stock, valued at $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius bought 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares in the company, valued at $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Stock Up 2.1%

NYSE:ELAN opened at $24.05 on Friday. The company’s 50-day simple moving average is $24.56 and its 200-day simple moving average is $24.01. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The stock has a market capitalization of $12.02 billion, a P/E ratio of -58.66, a P/E/G ratio of 1.41 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the business posted $0.26 EPS. Elanco Animal Health’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. TD Cowen boosted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. UBS Group increased their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. KeyCorp lifted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Citigroup boosted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.09.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.